Scientific Publications


PML (Progressive Multifocal Leukoencephalopathy
)

Werner GA and Huang D (2016) Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus. J Neurovirol. 2016 Dec;22(6):871-875.

Berger JR, Fox RJ.  (2016)  Reassessing the risk of natalizumab-associated PML.  J Neurovirol. 2016 Aug;22(4):533-5.

Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO.  (2014)  JC virus in CD34 and CD19 cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol. 71:596 – 602.

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B.  (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathyAnn. Neurol. 76, 802-812.

Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P. (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificityJ Infect Dis. Jul 1;204(1):103-14.

Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P. (2011) Boothpur R and Brennan D. C. (2010) Human polyoma viruses and disease with emphasis on clinical BK and JC. J. Clin. Virol. Doi 10.1416/j.jcv.2009.12.006

Swimm AI, Bornmann W, Jiang M, Imperiale MJ, Lukacher AE, Kalman D (2010) Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. J. Virol. 84, 4243-4251.

Lebeis SL, Kalman D. (2009) Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions. Cell Host Microbe 5:114-22.

 


 

Parkinson’s Disease

Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, Mao X, Shin JH, Lee Y, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Ko HS.  (2016)  Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegenerationJ Clin Invest. 126:2970-88.

Pagan F, Hebron M, Valadez EH, Tores-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Drew Falconer R, Ahn J, Li Z, Moussa C.  (2016)  Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies.  J Parkinsons Dis. 2016 Jul 11.

Wyse RK, Brundin P, Sherer TB.  (2016)  Nilotinib – Differentiating the Hope from the Hype. J Parkinsons Dis. 2016 Jul 12.

Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS, Dawson TM. (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3Science. Sep 30;353(6307). pii: aah3374.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. (2015) Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations.  Lancet Neurol. 14:855-66.

Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA. (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Hum Mol Genet. 23:2858-79.

Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS.  (2014)  The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease.  Sci Rep. 2014 May 2;4:4874.

Hebron ML, Lonskaya I, Moussa CE. (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson’s disease models. Hum Mol Genet. 22:3315-28.

Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Slikker W, Jr., Li S, Clark RA, Ali SF. (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson’s disease model. PLoS One. 8:e65129.

Schlatterer SD, Acker CM, Davies P. (2011)  c-Abl in neurodegenerative disease. J Mol Neurosci. 45:445-52.

Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, Li S. (2011)  Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson’s disease. J Neurosci. 31:157-63.

Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM. (2010)  Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc Natl Acad Sci U S A. 107:16691-6.

Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. (2003)  Science. 302:819-22.

 


 

Other Applications in Infectious Disease

Hawn TR, Shah JA, Kalman D. (2015)  New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev. Mar;264(1):344-62.

García M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D, Nabel GJ. (2012) Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med. 4:123ra24.

Reeves PM, Smith SK, Olson VA, Thorne SH, Bornmann W, Damon IK, Kalman D. (2011) Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol. 85(1):21-31.

Back to Top